Cryoport (CYRX) Q4 2025 earnings review
Strong Services Execution and Cash Injection, But EBITDA Profitability Timeline Slips
Cryoport finished FY25 with a top-line beat, generating $176.2M in revenue (+12% YoY) and exceeding the high end of its guidance. The core Life Sciences Services segment continues to be a powerful growth engine, driven by a 29% surge in commercial cell and gene therapy (CGT) support. The divestiture of CRYOPDP to DHL fundamentally transformed the balance sheet, leaving the company with a massive $411.2M in cash. However, the operational narrative has a flaw: despite management's previous goal to achieve positive adjusted EBITDA during 2025, the Q4 adjusted EBITDA loss reversed its improving trend, widening sequentially from $0.6M in Q3 to $1.4M in Q4. FY26 guidance projects decelerating top-line growth of 8-10%, reflecting continued macroeconomic caution and uneven demand in the Products segment.
🐂 Bull Case
The company now supports 20 commercial therapies (up from 14 last year) and 760 global clinical trials. Commercial CGT revenue grew 29% YoY in FY25, proving the long-term viability of this high-margin recurring revenue stream.
The DHL partnership and CRYOPDP divestiture infused significant capital. With $411.2M in cash and short-term investments, Cryoport has ample runway to fund facility buildouts (Paris, Santa Ana) and opportunistic buybacks without dilution.
🐻 Bear Case
Life Sciences Products (MVE) growth severely decelerated to 2% in Q4 (down from 15% in Q3). This segment's uneven recovery continues to drag on consolidated performance.
Management had guided toward reaching positive adjusted EBITDA in 2025. Instead, upfront investments in new facilities and services caused margins to compress sequentially, pushing true operational profitability further into the future.
⚖️ Verdict: ⚪
Neutral. The core services business is firing on all cylinders, and the balance sheet is pristine. However, a stalling path to profitability and a decelerating products segment cap near-term upside. Execution on FY26 facility launches will be critical to achieving operating leverage.
Key Themes
Commercial Cell & Gene Therapy is the Growth Engine
Revenue from supporting commercial CGTs continues its rapid ascent, growing 29% YoY to $33.4M in FY25. Cryoport's pipeline funnel is unparalleled: they support 760 global clinical trials (representing ~70% of the market), including 86 in Phase 3. With 13 BLA/MAA filings and 9 new therapy approvals expected in 2026, this high-margin, sticky revenue stream remains the core driver of the bullish thesis.
BioStorage/BioServices Integration Paying Off
The strategy to cross-sell storage and services to existing logistics clients is working. BioStorage/BioServices revenue accelerated to 22% YoY growth for FY25 ($18.4M). As clients look to consolidate vendors for complex, temperature-controlled supply chains, Cryoport is successfully capturing more wallet share per therapy.
DHL Strategic Partnership Validation
The completion of the CRYOPDP divestiture to DHL was a masterstroke. Not only did it generate over $112M in net income from discontinued operations, but it also allows Cryoport to leverage DHL's massive global logistics footprint, specifically enhancing their competitive positioning and market penetration in the EMEA and APAC regions.
Profitability Narrative Contradiction
Throughout H1 2025, management aggressively messaged a "pathway to profitability" and a return to positive adjusted EBITDA during the year. The data now contradicts this: adjusted EBITDA improved to -$0.6M in Q3, but unexpectedly reversed to -$1.4M in Q4. While management cites startup costs for new facilities (Paris, Santa Ana), the failure to cross the breakeven threshold raises questions about the true underlying cost structure of their expansion.
Life Sciences Products (MVE) Deceleration
The Products segment is showing highly erratic demand. After an encouraging 15% YoY growth print in Q3, growth decelerated sharply to just 2% YoY ($20.4M) in Q4. While management points to new innovations like the Fusion 800 Series, the inconsistent volume suggests post-COVID destocking and macro capital-expenditure hesitation have not been fully resolved.
Macro and Tariff Headwinds Limit Upside
Management explicitly cited "national economic factors, the global macroeconomic and geopolitical environment, supply chain constraints, inflationary pressures, any U.S. federal government shutdown, tariffs and other trade restrictions" as governors on FY26 guidance. Earlier in the year, management claimed they could pass tariff costs through surcharges, but the cautious 8-10% FY26 revenue guide suggests external macro factors are genuinely impacting client capital purchasing decisions.
Other KPIs
Stable. Up from 47.0% in 24Q4, driven by cost reduction initiatives implemented earlier in the year. However, services gross margin actually ticked down slightly to 48.6% (from 48.8% in 24Q4), offset by product margin improvement (to 46.8% from 45.1%).
Accelerating significantly year-over-year. This war chest, funded by the DHL transaction, allowed the company to comfortably repurchase 1.34 million shares ($10.0M) while funding massive CapEx projects like the Paris and Santa Ana Global Supply Chain Centers.
Guidance
Decelerating. The midpoint of $192M implies a 9.0% YoY growth rate. This is a step down from the 12% YoY growth achieved in FY25. Management framed this as an "appropriate starting point" balancing the strong CGT pipeline against global macroeconomic puts and takes.
Key Questions
Adjusted EBITDA Reversal
Adjusted EBITDA loss widened sequentially from Q3 to Q4 despite higher revenue. How much of this was driven by upfront costs for the Paris and Santa Ana facilities versus underlying margin compression, and when should we expect to cross the breakeven threshold?
Product Demand Volatility
Life Sciences Products growth dropped from 15% in Q3 to 2% in Q4. Is this a return to capital-expenditure hesitancy from your customers, or just a timing issue with specific large orders?
IntegriCell Revenue Contribution
With the IntegriCell facilities in Belgium and Texas now onboarding their first clients, what is the expected revenue ramp for this service line in the FY26 guidance?
DHL Partnership Economics
Now that the DHL partnership has been active for several months, what specific uplift are you seeing in win-rates or RFP inclusions in the EMEA and APAC regions as a direct result of this relationship?